- Home
- BEATW vs CCU Comparison
BEATW vs CCU Comparison
Compare BEATW & CCU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEATW
- CCU
- Stock Information
- Founded
- BEATW 2015
- CCU 1850
- Country
- BEATW United States
- CCU Chile
- Employees
- BEATW 21
- CCU N/A
- Industry
- BEATW Retail: Computer Software & Peripheral Equipment
- CCU Beverages (Production/Distribution)
- Sector
- BEATW Technology
- CCU Consumer Staples
- Exchange
- BEATW Nasdaq
- CCU Nasdaq
- Market Cap
- BEATW N/A
- CCU N/A
- IPO Year
- BEATW N/A
- CCU 1992
- Fundamental
- Price
- BEATW $0.60
- CCU $15.38
- Analyst Decision
- BEATW
- CCU Strong Sell
- Analyst Count
- BEATW 0
- CCU 2
- Target Price
- BEATW N/A
- CCU $9.70
- AVG Volume (30 Days)
- BEATW 4.7K
- CCU 291.8K
- Earning Date
- BEATW 03-14-2025
- CCU 05-07-2025
- Dividend Yield
- BEATW N/A
- CCU 2.44%
- EPS Growth
- BEATW N/A
- CCU 52.33
- EPS
- BEATW N/A
- CCU 0.44
- Revenue
- BEATW N/A
- CCU $2,922,923,314.00
- Revenue This Year
- BEATW N/A
- CCU $8.75
- Revenue Next Year
- BEATW N/A
- CCU $3.51
- P/E Ratio
- BEATW N/A
- CCU $17.84
- Revenue Growth
- BEATW N/A
- CCU 13.21
- 52 Week Low
- BEATW $0.50
- CCU $10.00
- 52 Week High
- BEATW $0.62
- CCU $15.68
- Technical
- Relative Strength Index (RSI)
- BEATW N/A
- CCU 56.48
- Support Level
- BEATW N/A
- CCU $15.14
- Resistance Level
- BEATW N/A
- CCU $15.42
- Average True Range (ATR)
- BEATW 0.00
- CCU 0.52
- MACD
- BEATW 0.00
- CCU 0.03
- Stochastic Oscillator
- BEATW 0.00
- CCU 84.05
About BEATW Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.